674 Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving ¹ <sup>7</sup> <sup>7</sup> Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune response
Anusha Muralidhar(Fred Hutch Cancer Center), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Zenghua Fan(University of California, San Francisco), Michael J. Evans(University of California, San Francisco), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Serena S. Kwek(University of California, San Francisco), Matthew D. Clark(City College of San Francisco), Karen Law(Fred Hutch Cancer Center), Averey Lea(University of California, San Francisco), Aram Lyu(Fred Hutch Cancer Center)
Cited by 0
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
|Annals of Oncology|2019|484
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
|Cell|2023|410
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
|Prostate Cancer and Prostatic Diseases|2021|224
Identification and Testing of Superior Reference Genes for a Starting Pool of Transcript Normalization in Arabidopsis
|Plant and Cell Physiology|2010|219